Andrew Melissa K, Bowles Susan K, Pawelec Graham, Haynes Laura, Kuchel George A, McNeil Shelly A, McElhaney Janet E
Division of Geriatric Medicine, Department of Medicine (Geriatrics), Dalhousie University, 5955 Veterans' Memorial Lane, Halifax, NS, Canada.
Canadian Center for Vaccinology, Halifax, NS, Canada.
Drugs Aging. 2019 Jan;36(1):29-37. doi: 10.1007/s40266-018-0597-4.
Influenza can lead to serious illness, particularly for older adults. In addition to short-term morbidity and mortality during the acute infection, recovery can be prolonged and often incomplete. This may lead to persistent declines in health and function, including catastrophic disability, which has dramatic implications for the well-being and support needs of older adults and their caregivers. All of this means that prevention of infection and effective treatment when illness has occurred are of paramount importance. In this narrative review, we discuss the effectiveness of influenza vaccines for the prevention of influenza illness and serious outcomes in older adults. We review evidence of vaccine effectiveness for older adults in comparison with younger age groups, and also highlight the importance of frailty as a determinant of vaccine effectiveness. We then turn our attention to the question of why older and frailer individuals have poorer vaccine responses, and consider changes in immune function and inflammatory responses. This sets the stage for a discussion of newer influenza vaccine products that have been developed with the aim of enhancing vaccine effectiveness in older adults. We review the available evidence on vaccine efficacy, effectiveness and cost benefits, consider the potential place of these innovations in clinical geriatric practice, and discuss international advisory committee recommendations on influenza vaccination in older adults. Finally, we highlight the importance of influenza prevention to support healthy aging, along with the need to improve vaccine coverage rates using available vaccine products, and to spur development of better influenza vaccines for older adults in the near future.
流感可导致严重疾病,尤其是对老年人而言。除了急性感染期间的短期发病和死亡外,恢复过程可能延长且往往不完全。这可能导致健康和功能持续下降,包括灾难性残疾,这对老年人及其护理人员的福祉和支持需求具有重大影响。所有这些都意味着预防感染以及在患病时进行有效治疗至关重要。在这篇叙述性综述中,我们讨论流感疫苗在预防老年人流感疾病及严重后果方面的有效性。我们回顾了与较年轻年龄组相比老年人疫苗有效性的证据,并强调衰弱作为疫苗有效性决定因素的重要性。然后我们将注意力转向为何年龄较大和身体较虚弱的个体疫苗反应较差的问题,并考虑免疫功能和炎症反应的变化。这为讨论旨在提高老年人疫苗有效性而研发的新型流感疫苗产品奠定了基础。我们回顾了关于疫苗效力、有效性和成本效益的现有证据,考虑这些创新在老年临床实践中的潜在地位,并讨论国际咨询委员会关于老年人流感疫苗接种的建议。最后,我们强调预防流感对支持健康老龄化的重要性,以及使用现有疫苗产品提高疫苗接种覆盖率的必要性,并推动在不久的将来研发出更适合老年人的流感疫苗。